[en] Alzheimer's disease (AD) is the most common form of neurodegenerative dementias worldwide. Amyloid-β deposition, neurofibrillary tangle formation and Neuroinflammation are the major pathogenetic mechanisms that in concert lead to memory dysfunction and decline of cognition. To date, there is no curative treatment for AD. Epidemiological analysis support the notion that sustained intake of non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk and delay the onset of AD. In contrast, therapeutic studies testing NSAID efficacy in AD patients have not yielded positive results. This suggests that either the investigated drugs have not addressed the mechanism of action required for mediating beneficial effects or that NSAIDs are effective at stages way before clinical onset of symptoms. The NSAIDs concerned are pleiotrophic in nature and interact with more than one pathomechanism. Therefore evidence for more than one neuroprotective action of NSAIDs has been put forward and it seems likely that some of the drugs act at multiple levels through more than one molecular mechanism. Some, even may not only be beneficial, but negative actions may be overruled by protective effects. Within these mechanisms, modulation of γ-secretase activity, the activation of the peroxisome proliferator-activated receptor-γ, binding to prostaglandin receptors or interactions at the blood-brain barrier may account for the observed protection from AD. This article reviews the current knowledge and views on the above mechanisms and critically discusses current obstacles and the potential as future AD therapeutics.
Disciplines :
Neurology
Author, co-author :
HENEKA, Michael ; Department of Neurology, Clinical Neurosciences, Unversity of Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany. michael.heneka@ukb.uni-bonn.de
Kummer, M P; Clinical Neurosciences, Department of Neurology, Unversity of Bonn, D-53127 Bonn, Germany
Weggen, S; Molecular Neuropathology Group, Department of Neuropathology, Heinrich-Heine-University, D-40225 Duesseldorf, Germany
Bulic, B; Research Group Chemical Biology of Neurodegenerative Diseases, Center of Advanced European Studies and Research, D-53175 Bonn, Germany
Multhaup, G; Institute of Chemistry and Biochemistry, Free University of Berlin, D-14195 Berlin, Germany
Münter, L; Institute of Chemistry and Biochemistry, Free University of Berlin, D-14195 Berlin, Germany
Hüll, M; Center of Geriatric Medicine and Gerontology, University of Freiburg, D-79106 Freiburg im Breisgau, Germany
Pflanzner, T; Institute of Pathobiochemistry, Molecular Neurodegeneration, University Medical Center of the Johannes Gutenberg University Mainz, 55099 Mainz, Germany
Pietrzik, C U; Institute of Pathobiochemistry, Molecular Neurodegeneration, University Medical Center of the Johannes Gutenberg University Mainz, 55099 Mainz, Germany
External co-authors :
yes
Language :
English
Title :
Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease.
Wancata J, Musalek M, Alexandrowicz R, Krautgartner M. Number of dementia sufferers in Europe between the years 2000 and 2050. Eur Psychiatry 18(6): 306-313 (2003).
McGeer PL, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 335(8696): 1037 (1990).
Launer L. Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer's disease: dissecting the epidemiological evidence. Drugs 63(8): 731-739 (2003).
Cole GM, Morihara T, Lim GP, Yang F, Begum A, Frautschy SA. NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models. Ann N Y Acad Sci 1035: 68-84 (2004).
Gasparini L, Ongini E, Wenk G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J Neurochem 91(3): 521-536 (2004).
Leuchtenberger S, Beher D, Weggen S. Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal antiinflammatory drugs and beyond. Curr Pharm Des 12(33): 4337-4355 (2006).
Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 18(7): 790-804 (2004).
Heneka MT, Landreth GE, Feinstein DL. Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease. Ann Neurol 49(2): 276 (2001).
Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 20(2): 558-567 (2000).
Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128(Pt 6): 1442-1453 (2005).
Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDs and enantiomers of flurbiprofen target gammasecretase and lower Abeta 42 in vivo. J Clin Invest 112(3): 440-449 (2003).
Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414(6860): 212-216 (2001).
Hirohata M, Ono K, Naiki H, Yamada M. Non-steroidal antiinflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Neuropharmacology 49(7): 1088-1099 (2005).
Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 23(30): 9796-9804 (2003).
Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci USA 103(2): 443-448 (2006).
Morihara T, Teter B, Yang F, Lim GP, Boudinot S, Boudinot FD, et al. Ibuprofen suppresses interleukin-1beta induction of proamyloidogenic alpha1-antichymotrypsin to ameliorate betaamyloid (Abeta) pathology in Alzheimer's models. Neuropsychopharmacology 30(6): 1111-1120 (2005).
int' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345(21): 1515-1521 (2001).
Szekely CA, Green RC, Breitner JCS, Østbye T, Beiser AS, Corrada MM, et al. No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70(24): 2291-2298 (2008).
Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302(23): 2557-2564 (2009).
Aisen PS, Thal LJ, Ferris SH, Assaid C, Nessly ML, Giuliani MJ, et al. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Curr Alzheimer Res 5(1): 73-82 (2008).
Pasqualetti P, Bonomini C, Dal Forno G, Paulon L, Sinforiani E, Marra C, et al. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. Aging Clin Exp Res 21(2): 102-110 (2009).
Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20(5): 649-688 (1999).
Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58(4): 726-741 (2006).
Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferatoractivated receptor gamma and metabolic disease. Annu Rev Biochem 70: 341-367 (2001).
Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437(7059): 759-763 (2005).
Diradourian C, Girard J, Pégorier J. Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 87(1): 33-38 (2005).
McKay LI, Cidlowski JA. Molecular control of immune/ inflammatory responses: interactions between nuclear factorkappa B and steroid receptor-signaling pathways. Endocr Rev 20(4): 435-459 (1999).
Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2(10): 748-759 (2002).
Ghisletti S, Huang W, Ogawa S, Pascual G, Lin M, Willson TM, et al. Parallel SUMOylation-dependent pathways mediate gene-and signal-specific transrepression by LXRs and PPARgamma. Mol Cell 25(1): 57-70 (2007).
Ogawa S, Lozach J, Benner C, Pascual G, Tangirala RK, Westin S, et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122(5): 707-721 (2005).
Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11(6): 779-791 (1997).
Bernardo A, Minghetti L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des 12(1): 93-109 (2006).
Price DL, Tanzi RE, Borchelt DR, Sisodia SS. Alzheimer's disease: genetic studies and transgenic models. Annu Rev Genet 32: 461-493 (1998).
Sly LM, Krzesicki RF, Brashler JR, Buhl AE, McKinley DD, Carter DB, et al. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res Bull 56(6): 581-588 (2001).
Lee SC, Zhao ML, Hirano A, Dickson DW. Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques. J Neuropathol Exp Neurol 58(11): 1163-1169 (1999).
Vodovotz Y, Lucia MS, Flanders KC, Chesler L, Xie QW, Smith TW, et al. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J Exp Med 184(4): 1425-1433 (1996).
de la Monte SM, Wands JR. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis 9(2): 167-181 (2006).
Kielian T, Drew PD. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J Neurosci Res 71(3): 315-325 (2003).
Landreth GE, Heneka MT. Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol Aging 22(6): 937-944 (2001).
Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal antiinflammatory drugs. J Biol Chem 272(6): 3406-3410 (1997).
Heneka MT, Klockgether T, Feinstein DL. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 20(18): 6862-6867 (2000).
Heneka MT, Feinstein DL, Galea E, Gleichmann M, Wüllner U, Klockgether T. Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J Neuroimmunol 100(1-2): 156-168 (1999).
Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 20(2): 558-567 (2000).
Kim EJ, Kwon KJ, Park JY, Lee SH, Moon CH, Baik EJ. Effects of peroxisome proliferator-activated receptor agonists on LPSinduced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res 941(1-2): 1-10 (2002).
Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martínez A, Perez-Castillo A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem 280(22): 21453-21462 (2005).
Maeshiba Y, Kiyota Y, Yamashita K, Yoshimura Y, Motohashi M, Tanayama S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 47(1): 29-35 (1997).
Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23(20): 7504-7509 (2003).
Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, et al. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation 2:22 (2005).
Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, Rosa-Neto P, et al. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 28(37): 9287-9296 (2008).
Sastre M, Klockgether T, Heneka MT. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci 24(2-3): 167-176 (2006).
Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 24(48): 10908-10917 (2004).
Inestrosa NC, Godoy JA, Quintanilla RA, Koenig CS, Bronfman M. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp Cell Res 304(1): 91-104 (2005).
Fuentealba RA, Farias G, Scheu J, Bronfman M, Marzolo MP, Inestrosa NC. Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease. Brain Res Rev 47(1-3): 275-289 (2004).
Zhao X, Ou Z, Grotta JC, Waxham N, Aronowski J. Peroxisomeproliferator-activated receptor-gamma (PPARgamma) activation protects neurons from NMDA excitotoxicity. Brain Res 1073-1074: 460-469 (2006).
Wada K, Nakajima A, Katayama K, Kudo C, Shibuya A, Kubota N, et al. Peroxisome proliferator-activated receptor gammamediated regulation of neural stem cell proliferation and differentiation. J Biol Chem 281(18): 12673-12681 (2006).
Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 199(2): 265-273 (2006).
Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging 27(2): 190-198 (2006).
Risner ME, Saunders AM, Altman JFB, Ormandy GC, Craft S, Foley IM, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6(4): 246-254 (2006).
Chalimoniuk M, King-Pospisil K, Pedersen WA, Malecki A, Wylegala E, Mattson MP, et al. Arachidonic acid increases choline acetyltransferase activity in spinal cord neurons through a protein kinase C-mediated mechanism. J Neurochem 90(3): 629-636 (2004).
Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154(7): 635-641 (2001).
Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51(4): 1256-1262 (2002).
Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging [E. pub ahead of print].
Hamilton G, Proitsi P, Jehu L, Morgan A, Williams J, O'Donovan MC, et al. Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci. Am. J. Med. Genet. B Neuropsychiatr. Genet 144B(4): 508-516 (2007).
Stumvoll M, Häring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes. 2002 Aug;51(8):2341-2347.
Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26(1): 76-80 (2000).
Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20(3): 284-287 (1998).
Frederiksen L, Brødbaek K, Fenger M, Jørgensen T, Borch-Johnsen K, Madsbad S, et al. Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 87(8): 3989-3992 (2002).
Scacchi R, Pinto A, Gambina G, Rosano A, Corbo RM. The peroxisome proliferator-activated receptor gamma (PPAR-gamma2) Pro12Ala polymorphism is associated with higher risk for Alzheimer's disease in octogenarians. Brain Res 1139: 1-5 (2007).
Yermakova AV, O'Banion MK. Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol Aging 22(6): 823-836 (2001).
Hoozemans JJM, Veerhuis R, Rozemuller AJM, Arendt T, Eikelenboom P. Neuronal COX-2 expression and phosphorylation of pRb precede p38 MAPK activation and neurofibrillary changes in AD temporal cortex. Neurobiol Dis 15(3): 492-499 (2004).
Hoozemans JJ, Rozemuller AJ, Janssen I, De Groot CJ, Veerhuis R, Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol 101(1): 2-8 (2001).
Yermakova AV, Rollins J, Callahan LM, Rogers J, O'Banion MK. Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol 58(11): 1135-1146 (1999).
Matousek SB, Hein AM, Shaftel SS, Olschowka JA, Kyrkanides S, O'Banion MK. Cyclooxygenase-1 mediates prostaglandin E(2) elevation and contextual memory impairment in a model of sustained hippocampal interleukin-1beta expression. J Neurochem 114(1): 247-258 (2010).
Candelario-Jalil E, González-Falcón A, García-Cabrera M, Alvarez D, Al-Dalain S, Martínez G, et al. Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. J Neurochem 86(3): 545-555 (2003).
Choi S, Bosetti F. Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging 1(2): 234-244 (2009).
Choi S, Langenbach R, Bosetti F. Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharideinduced inflammatory response and brain injury. FASEB J 22(5): 1491-1501 (2008).
Candelario-Jalil E, de Oliveira ACP, Gräf S, Bhatia HS, Hüll M, Muñoz E, et al. Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation 4: 25 (2007).
Coma M, Serenó L, Da Rocha-Souto B, Scotton TC, España J, Sánchez MB, et al. Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 38(3): 482-491 (2010).
Frautschy SA. Thinking outside the box about COX-1 in Alzheimer's disease. Neurobiol Dis 38(3): 492-494 (2010).
Waschbisch A, Fiebich BL, Akundi RS, Schmitz ML, Hoozemans JJM, Candelario-Jalil E, et al. Interleukin-1 beta-induced expression of the prostaglandin E-receptor subtype EP3 in U373 astrocytoma cells depends on protein kinase C and nuclear factor-kappaB. J Neurochem 96(3): 680-693 (2006).
Slawik H, Volk B, Fiebich B, Hüll M. Microglial expression of prostaglandin EP3 receptor in excitotoxic lesions in the rat striatum. Neurochem Int 45(5): 653-660 (2004).
Mohri I, Kadoyama K, Kanekiyo T, Sato Y, Kagitani-Shimono K, Saito Y, et al. Hematopoietic prostaglandin D synthase and DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease. J Neuropathol Exp Neurol 66(6): 469-480 (2007).
Keene CD, Chang RC, Lopez-Yglesias AH, Shalloway BR, Sokal I, Li X, et al. Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic alzheimer's disease mice by transplanta tion with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow. Am J Pathol 177(1): 346-354 (2010).
Hoozemans JJM, Veerhuis R, Janssen I, van Elk E, Rozemuller AJM, Eikelenboom P. The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E(2) secretion by cultured human adult microglia: implications for Alzheimer's disease. Brain Res 951(2): 218-226 (2002).
Birkinshaw TN, Teague SJ, Beech C, Bonnert RV, Hill S, Patel A, et al. Discovery of potent CRTh2 (DP2) receptor antagonists. Bioorg Med Chem Lett 16(16): 4287-4290 (2006).
Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 110(4): 1129-1134 (2009).
Tomita T. Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev Neurother 9(5): 661-679 (2009).
Kopan R, Ilagan MXG. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137(2): 216-233 (2009).
Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials [Internet]. 2010 Aug 17;Available from: http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=499794
Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414(6860): 212-216 (2001).
Takahashi Y, Hayashi I, Tominari Y, Rikimaru K, Morohashi Y, Kan T, et al. Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J Biol Chem 278(20): 18664-18670 (2003).
Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, et al. Modulation of γ-Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease. Neuron 67(5): 769-780 (2010).
Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem 278(33): 30748-30754 (2003).
Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gammasecretase activity. J Biol Chem 278(34): 31831-31837 (2003).
Fraering PC, Ye W, Strub J, Dolios G, LaVoie MJ, Ostaszewski BL, et al. Purification and characterization of the human gammasecretase complex. Biochemistry 43(30): 9774-9789 (2004).
Sagi SA, Weggen S, Eriksen J, Golde TE, Koo EH. The noncyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production. J Biol Chem 278(34): 31825-31830 (2003).
Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gammasecretase activity. J Biol Chem 278(34): 31831-31837 (2003).
Richter L, Munter L, Ness J, Hildebrand PW, Dasari M, Unterreitmeier S, et al. Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proc Natl Acad Sci USA 107(33): 14597-14602 (2010).
Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48(3): 626-632 (1997).
Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JCS, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23(4): 159-169 (2004).
Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70(19): 1672-1677 (2008).
Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JCS. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 59(6): 880-886 (2002).
Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, et al. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal antiinflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22(6): 2246-2254 (2002).
Kotilinek LA, Westerman MA, Wang Q, Panizzon K, Lim GP, Simonyi A, et al. Cyclooxygenase-2 inhibition improves amyloidbeta-mediated suppression of memory and synaptic plasticity. Brain 131(Pt 3): 651-664 (2008).
Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20(15): 5709-5714 (2000).
McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, et al. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 1207: 225-236 (2008).
Quinn J, Montine T, Morrow J, Woodward WR, Kulhanek D, Eckenstein F. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J. Neuroimmunol 137(1-2): 32-41 (2003).
Sung S, Yang H, Uryu K, Lee EB, Zhao L, Shineman D, et al. Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol 165(6): 2197-2206 (2004).
Imbimbo BP. An update on the efficacy of non-steroidal antiinflammatory drugs in Alzheimer's disease. Expert Opin Investig Drugs 18(8): 1147-1168 (2009).
McEvoy GK, Snow EK, Kester L. Ahfs Drug Information 2006. 1st ed. American Society of Health-System Pharmacists (2006).
Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43(8): 1609-1611 (1993).
Herzig MC, Van Nostrand WE, Jucker M. Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. Brain Pathol 16(1): 40-54 (2006).
Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 7(6): 483-493 (2008).
Mannila A, Rautio J, Lehtonen M, Järvinen T, Savolainen J. Inefficient central nervous system delivery limits the use of ibuprofen in neurodegenerative diseases. Eur J Pharm Sci 24(1): 101-105 (2005).
Mannila A, Kumpulainen E, Lehtonen M, Heikkinen M, Laisalmi M, Salo T, et al. Plasma and cerebrospinal fluid concentrations of indomethacin in children after intravenous administration. J Clin Pharmacol 47(1): 94-100 (2007).
Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, et al. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord 21(4): 292-299 (2007).
Rivkin A, Ahearn SP, Chichetti SM, Kim YR, Li C, Rosenau A, et al. Piperazinyl pyrimidine derivatives as potent gamma-secretase modulators. Bioorg Med Chem Lett 20(3): 1269-1271 (2010).
Rivkin A, Ahearn SP, Chichetti SM, Hamblett CL, Garcia Y, Martinez M, et al. Purine derivatives as potent gamma-secretase modulators. Bioorg Med Chem Lett 20(7): 2279-2282 (2010).
Caldwell JP, Bennett CE, McCracken TM, Mazzola RD, Bara T, Buevich A, et al. Iminoheterocycles as gamma-secretase modulators. Bioorg Med Chem Lett 20(18): 5380-5384 (2010).
Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, et al. Acute Effect on the Abeta Isoform Pattern in CSF in Response to gamma-Secretase Modulator and Inhibitor Treatment in Dogs. J Alzheimers Dis [Internet]. 2010 Jul 15 [cited 2010 Jul 23];Available from: http://www.ncbi.nlm.nih.gov/pubmed/20634579
Zettl H, Weggen S, Schneider P, Schneider G. Exploring the chemical space of gamma-secretase modulators. Trends Pharmacol Sci [Internet]. 2010 Jun 28 [cited 2010 Jul 23];Available from: http://www.ncbi.nlm.nih.gov/pubmed/20591508
Bayer TA, Cappai R, Masters CL, Beyreuther K, Multhaup G. It all sticks together--the APP-related family of proteins and Alzheimer's disease. Mol Psychiatry 4(6): 524-528 (1999).
Rosen DR, Martin-Morris L, Luo LQ, White K. A Drosophila gene encoding a protein resembling the human beta-amyloid protein precursor. Proc Natl Acad Sci USA 86(7): 2478-2482 (1989).
Daigle I, Li C. apl-1, a Caenorhabditis elegans gene encoding a protein related to the human beta-amyloid protein precursor. Proc Natl Acad Sci USA 90(24): 12045-12049 (1993).
Dawson GR, Seabrook GR, Zheng H, Smith DW, Graham S, O'Dowd G, et al. Age-related cognitive deficits, impaired longterm potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience 90(1): 1-13 (1999).
Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, Rülicke T, et al. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci 20(21): 7951-7963 (2000).
Chen C, Oh S, Hinman JD, Abraham CR. Visualization of APP dimerization and APP-Notch2 heterodimerization in living cells using bimolecular fluorescence complementation. J Neurochem 97(1): 30-43 (2006).
Gralle M, Botelho MG, Wouters FS. Neuroprotective secreted amyloid precursor protein acts by disrupting amyloid precursor protein dimers. J Biol Chem 284(22): 15016-15025 (2009).
Kaden D, Munter L, Joshi M, Treiber C, Weise C, Bethge T, et al. Homophilic interactions of the amyloid precursor protein (APP) ectodomain are regulated by the loop region and affect beta-secretase cleavage of APP. J Biol Chem 283(11): 7271-7279 (2008).
Rossjohn J, Cappai R, Feil SC, Henry A, McKinstry WJ, Galatis D, et al. Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nat Struct Biol 6(4):327-331 (1999).
Scheuermann S, Hambsch B, Hesse L, Stumm J, Schmidt C, Beher D, et al. Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's disease. J Biol Chem 276(36): 33923-33929 (2001).
Wang Y, Ha Y. The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domain. Mol Cell 15(3): 343-353 (2004).
Kaden D, Voigt P, Munter L, Bobowski KD, Schaefer M, Multhaup G. Subcellular localization and dimerization of APLP1 are strikingly different from APP and APLP2. J Cell Sci 122(Pt 3): 368-377 (2009).
Soba P, Eggert S, Wagner K, Zentgraf H, Siehl K, Kreger S, et al. Homo-and heterodimerization of APP family members promotes intercellular adhesion. EMBO J 24(20): 3624-3634 (2005).
Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 248(4959): 1122-1124 (1990).
Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 96(7): 3922-3927 (1999).
Turner RT, Koelsch G, Hong L, Castanheira P, Ermolieff J, Ghosh AK, et al. Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design. Biochemistry 40(34): 10001-10006 (2001).
Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286(5440): 735-741 (1999).
Fluhrer R, Multhaup G, Schlicksupp A, Okochi M, Takeda M, Lammich S, et al. Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation. J Biol Chem 278(8): 5531-5538 (2003).
Schmechel A, Zentgraf H, Scheuermann S, Fritz G, Pipkorn R, Reed J, et al. Alzheimer beta-amyloid homodimers facilitate A beta fibrillization and the generation of conformational antibodies. J Biol Chem 278(37): 35317-35324.
Gu Y, Misonou H, Sato T, Dohmae N, Takio K, Ihara Y. Distinct intramembrane cleavage of the beta-amyloid precursor protein family resembling gamma-secretase-like cleavage of Notch. J Biol Chem 276(38): 35235-35238 (2001).
Kakuda N, Funamoto S, Yagishita S, Takami M, Osawa S, Dohmae N, et al. Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from betacarboxyl-terminal fragment by gamma-secretase. J Biol Chem 281(21): 14776-14786 (2006).
Munter L, Voigt P, Harmeier A, Kaden D, Gottschalk KE, Weise C, et al. GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. EMBO J 26(6): 1702-1712 (2007).
Zhao G, Mao G, Tan J, Dong Y, Cui M, Kim S, et al. Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein. J Biol Chem 279(49): 50647-50650 (2004).
Endres K, Postina R, Schroeder A, Mueller U, Fahrenholz F. Shedding of the amyloid precursor protein-like protein APLP2 by disintegrin-metalloproteinases. FEBS J 272(22): 5808-5820 (2005).
Pastorino L, Ikin AF, Lamprianou S, Vacaresse N, Revelli JP, Platt K, et al. BACE (beta-secretase) modulates the processing of APLP2 in vivo. Mol Cell Neurosci 25(4): 642-649 (2004).
Minogue AM, Stubbs AK, Frigerio CS, Boland B, Fadeeva JV, Tang J, et al. gamma-secretase processing of APLP1 leads to the production of a p3-like peptide that does not aggregate and is not toxic to neurons. Brain Res 1262: 89-99 (2009).
Eggert S, Paliga K, Soba P, Evin G, Masters CL, Weidemann A, et al. The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation. J Biol Chem 279(18): 18146-18156 (2004).
Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, Horikoshi Y, et al. Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J Neurosci 25(2): 436-445 (2005).
Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, et al. gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci 29(41): 13042-13052 (2009).
Harmeier A, Wozny C, Rost BR, Munter L, Hua H, Georgiev O, et al. Role of amyloid-beta glycine 33 in oligomerization, toxicity, and neuronal plasticity. J Neurosci 29(23): 7582-7590 (2009).
Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature Nov 414(6860): 212-216 (2001).
Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9(5): 387-398 (2010).
McCarron MO, Nicoll JA, Stewart J, Ironside JW, Mann DM, Love S, et al. The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. J Neuropathol Exp Neurol 58(7): 711-718 (1999).
Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 68(21): 1809-1814 (2007).
Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7(1): 41-53 (2006).
Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 3(2): 90-105, 51 (2003).
Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 407(6801): 249-257 (2000).
Desai BS, Schneider JA, Li J, Carvey PM, Hendey B. Evidence of angiogenic vessels in Alzheimer's disease. J Neural Transm 116(5): 587-597 (2009).
Bouras C, Kövari E, Herrmann FR, Rivara C, Bailey TL, von Gunten A, et al. Stereologic analysis of microvascular morphology in the elderly: Alzheimer disease pathology and cognitive status. J Neuropathol Exp Neurol 65(3): 235-244 (2006).
Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, et al. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med 11(9): 959-965 (2005).
Blanc EM, Toborek M, Mark RJ, Hennig B, Mattson MP. Amyloid beta-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells. J Neurochem 68(5): 1870-1881 (1997).
Gonzalez-Velasquez FJ, Kotarek JA, Moss MA. Soluble aggregates of the amyloid-beta protein selectively stimulate permeability in human brain microvascular endothelial monolayers. J Neurochem 107(2): 466-477 (2008).
Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380(6570): 168-171 (1996).
Vukic V, Callaghan D, Walker D, Lue L, Liu QY, Couraud P, et al. Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis 34(1): 95-106 (2009).
Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8: 67-113 (1992).
Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 42(7): 1007-1017 (2001).
Van Eck M, Pennings M, Hoekstra M, Out R, Van Berkel TJ. Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 16(3): 307-315 (2005).
Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, et al. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 280(52): 43236-43242 (2005).
Akanuma S, Ohtsuki S, Doi Y, Tachikawa M, Ito S, Hori S, et al. ATP-binding cassette transporter A1 (ABCA1) deficiency does not attenuate the brain-to-blood efflux transport of human amyloid-beta peptide (1-40) at the blood-brain barrier. Neurochem Int 52(6): 956-961 (2008).
Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95(26): 15665-15670 (1998).
Xiong H, Callaghan D, Jones A, Bai J, Rasquinha I, Smith C, et al. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides. J Neurosci 29(17): 5463-5475 (2009).
Tai LM, Loughlin AJ, Male DK, Romero IA. P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-beta. J Cereb Blood Flow Metab 29(6): 1079-1083 (2009).
Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115(11): 3285-3290 (2005).
Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, et al. MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 17(4): 347-353 (2007).
Ito S, Ohtsuki S, Terasaki T. Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neurosci Res 56(3): 246-252 (2006).
Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. Nature 337(6203): 184-187 (1989).
Schlachetzki F, Zhu C, Pardridge WM. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem 81(1): 203-206 (2002).
Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, et al. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 25(50): 11495-11503 (2005).
Schmidt AM, Mora R, Cao R, Yan SD, Brett J, Ramakrishnan R, et al. The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem 269(13): 9882-9888 (1994).
Xie J, Reverdatto S, Frolov A, Hoffmann R, Burz DS, Shekhtman A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem 283(40): 27255-27269 (2008).
Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS, et al. Human blood-brain barrier receptors for Alzheimer's amyloidbeta 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest 102(4): 734-743 (1998).
Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9(7): 907-913 (2003).
LaRue B, Hogg E, Sagare A, Jovanovic S, Maness L, Maurer C, et al. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice. J Neurosci Methods 138(1-2): 233-242 (2004).
Demeule M, Poirier J, Jodoin J, Bertrand Y, Desrosiers RR, Dagenais C, et al. High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J Neurochem 83(4): 924-933 (2002).
Jaeger S, Pietrzik CU. Functional role of lipoprotein receptors in Alzheimer's disease. Curr Alzheimer Res 5(1): 15-25 (2008).
Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, et al. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 106(9): 1159-1166 (2000).
Martin AM, Kuhlmann C, Trossbach S, Jaeger S, Waldron E, Roebroek A, et al. The functional role of the second NPXY motif of the LRP1 beta-chain in tissue-type plasminogen activator-mediated activation of N-methyl-D-aspartate receptors. J Biol Chem 283(18): 12004-12013 (2008).
Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J 21(21): 5691-5700 (2002).
Pietrzik CU, Yoon I, Jaeger S, Busse T, Weggen S, Koo EH. FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J Neurosci 24(17): 4259-4265 (2004).
Shibata Y, Muramatsu T, Hirai M, Inui T, Kimura T, Saito H, et al. Nuclear targeting by the growth factor midkine. Mol Cell Biol 22(19): 6788-6796 (2002).
Waldron E, Heilig C, Schweitzer A, Nadella N, Jaeger S, Martin AM, et al. LRP1 modulates APP trafficking along early compartments of the secretory pathway. Neurobiol Dis 31(2): 188-197 (2008).
Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106(12): 1489-1499 (2000).
Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43(3): 333-344 (2004).
Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13(9): 1029-1031 (2007).
Nazer B, Hong S, Selkoe DJ. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. Neurobiol Dis 30(1): 94-102 (2008).
Herz J, Clouthier DE, Hammer RE. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell 71(3): 411-421 (1992).
Pflanzner T, Janko MC, André-Dohmen B, Reuss S, Weggen S, Roebroek AJM, et al. LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier. Neurobiol Aging [Internet]. 2010 Jul 12 [cited 2010 Jul 21];Available from: http://www.ncbi.nlm.nih.gov/pubmed/20630619
Reekmans SM, Pflanzner T, Gordts PLSM, Isbert S, Zimmermann P, Annaert W, et al. Inactivation of the proximal NPXY motif impairs early steps in LRP1 biosynthesis. Cell Mol Life Sci 67(1): 135-145 (2010).
Roebroek AJM, Reekmans S, Lauwers A, Feyaerts N, Smeijers L, Hartmann D. Mutant Lrp1 knock-in mice generated by recombinase-mediated cassette exchange reveal differential importance of the NPXY motifs in the intracellular domain of LRP1 for normal fetal development. Mol Cell Biol 26(2): 605-616 (2006).
DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98(15): 8850-8855 (2001).
Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31: 175-193 (2008).
Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1(1): 24 (2004).
Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9(4): 448-452 (2003).
Choi J, Jenkins BG, Carreras I, Kaymakcalan S, Cormier K, Kowall NW, et al. Anti-inflammatory treatment in AD mice protects against neuronal pathology. Exp Neurol 223(2): 377-384 (2010).
Fukuda M, Kitaichi K, Abe F, Fujimoto Y, Takagi K, Takagi K, et al. Altered brain penetration of diclofenac and mefenamic acid, but not acetaminophen, in Shiga-like toxin II-treated mice. J Pharmacol Sci 97(4): 525-532 (2005).
Parepally JMR, Mandula H, Smith QR. Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin. Pharm Res 23(5): 873-881 (2006).
Prins LHA, du Preez JL, van Dyk S, Malan SF. Polycyclic cage structures as carrier molecules for neuroprotective non-steroidal anti-inflammatory drugs. Eur J Med Chem 44(6): 2577-2582 (2009).
Perioli L, Ambrogi V, Bernardini C, Grandolini G, Ricci M, Giovagnoli S, et al. Potential prodrugs of non-steroidal antiinflammatory agents for targeted drug delivery to the CNS. Eur J Med Chem 39(8): 715-727 (2004).
Zuckerman SL, Mirro R, Armstead WM, Shibata M, Leffler CW. Indomethacin reduces ischemia-induced alteration of blood-brain barrier transport in piglets. Am J Physiol 266(6 Pt 2): H2198-2203 (1994).
Candelario-Jalil E, González-Falcón A, García-Cabrera M, León OS, Fiebich BL. Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats. J Neurochem 100(4): 1108-1120 (2007).
Candelario-Jalil E, Taheri S, Yang Y, Sood R, Grossetete M, Estrada EY, et al. Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther 323(2): 488-498 (2007).
Germann B, Neuhaus W, Hofer-Warbinek R, Noe CR. Applying blood-brain barrier in vitro models to study the influence of drugs on endothelial cells--effects of selected COX-inhibitors. Pharmazie 63(4): 303-307 (2008).
Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 7: 17 (2009).
Toma L, Stancu CS, Botez GM, Sima AV, Simionescu M. Irreversibly glycated LDL induce oxidative and inflammatory state in human endothelial cells; added effect of high glucose. Biochem Biophys Res Commun 390(3): 877-882 (2009).
Wendt T, Bucciarelli L, Qu W, Lu Y, Yan SF, Stern DM, et al. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep 4(3): 228-237 (2002).
Guo X, Huang Q, Chen B, Wang S, Li Q, Zhu Y, et al. Advanced glycation end products induce actin rearrangement and subsequent hyperpermeability of endothelial cells. APMIS 114(12): 874-883 (2006).
Warboys CM, Toh H, Fraser PA. Role of NADPH oxidase in retinal microvascular permeability increase by RAGE activation. Invest Ophthalmol Vis Sci 50(3): 1319-1328 (2009).
Yamamoto K, Kitayama W, Denda A, Sasahira T, Kuniyasu H, Kirita T. Expression of receptor for advanced glycation end products during rat tongue carcinogenesis by 4-nitroquinoline 1-oxide and effect of a selective cyclooxygenase-2 inhibitor, etodolac. Pathobiology 73(6): 317-324 (2006).
Chan ESL, Zhang H, Fernandez P, Edelman SD, Pillinger MH, Ragolia L, et al. Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk. Arthritis Res Ther 9(1): R4 (2007).
Dahan A, Amidon GL. MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int J Pharm 386(1-2): 216-220 (2010).
Yu L, Wu WKK, Li ZJ, Liu QC, Li HT, Wu YC, et al. Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity. Mol Pharmacol 75(6): 1364-1373 (2009).
Jaeger LB, Dohgu S, Sultana R, Lynch JL, Owen JB, Erickson MA, et al. Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease. Brain Behav Immun 23(4): 507-517 (2009).
Angelini A, Iezzi M, Di Febbo C, Di Ilio C, Cuccurullo F, Porreca E. Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal antiinflammatory drugs. Oncol Rep 20(4): 731-735 (2008).
O'Connor R, Heenan M, Connolly L, Larkin A, Clynes M. Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Res 24(2A): 457-464 (2004).
Viñals M, Bermúdez I, Llaverias G, Alegret M, Sanchez RM, Vázquez-Carrera M, et al. Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages. Cardiovasc Res 66(1): 141-149 (2005).
Xia W, Zhao T, Lv J, Xu S, Shi J, Wang S, et al. Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner. J Cell Biochem 108(1): 181-194 (2009).
Zatelli MC, Molè D, Tagliati F, Minoia M, Ambrosio MR, degli Uberti E. Cyclo-oxygenase 2 modulates chemoresistance in breast cancer cells involving NF-kappaB. Cell Oncol 31(6): 457-465 (2009).
Zrieki A, Farinotti R, Buyse M. Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm Res 25(9): 1991-2001 (2008).
